Sign up to save your podcasts
Or
Share Green Lights & Red Flags in Breast Cancer Care — The Story of Emma’s Missed Diagnosis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Green Lights & Red Flags in Breast Cancer Care — The Story of Emma’s Missed Diagnosis
Imagine being told you’re cancer-free — twice — only for the cancer to come back a year later.
In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares the true story of Emma, a breast cancer patient who followed every standard guideline and still faced a devastating recurrence. Despite surgery, chemo, and a “low concern” blood test, Emma’s cancer returned because her care relied on incomplete data and one-size-fits-all testing.
Dr. Prato explains how false reassurance from small genetic panels can leave critical pathways and immune signals undetected. He shows how precision oncology — using deep DNA/RNA sequencing, immune profiling, and spatial biology — reveals the full picture behind cancer recurrence. By combining this information with custom drug design, microdosed chemo, and interventional oncology, Envita helped Emma achieve remission safely and sustainably.
🎯 What You’ll Learn in This Episode:
- Why small blood tests can falsely reassure patients
- How most genetic panels miss key mutations and immune factors
- What deep mapping reveals about tumor recurrence
- How CIPI (Chemo-Immuno-Precision Injection) targets tumors directly
- Why precision oncology offers better outcomes with fewer side effects
📊 Precision oncology replaces guesswork with molecular-level accuracy — transforming how cancer is detected, treated, and prevented from coming back.
“False reassurance can be deadly. Precision testing finds what others miss.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493
View all episodes
By Dr. Dino Prato - Envita Medical CentersImagine being told you’re cancer-free — twice — only for the cancer to come back a year later.
In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares the true story of Emma, a breast cancer patient who followed every standard guideline and still faced a devastating recurrence. Despite surgery, chemo, and a “low concern” blood test, Emma’s cancer returned because her care relied on incomplete data and one-size-fits-all testing.
Dr. Prato explains how false reassurance from small genetic panels can leave critical pathways and immune signals undetected. He shows how precision oncology — using deep DNA/RNA sequencing, immune profiling, and spatial biology — reveals the full picture behind cancer recurrence. By combining this information with custom drug design, microdosed chemo, and interventional oncology, Envita helped Emma achieve remission safely and sustainably.
🎯 What You’ll Learn in This Episode:
- Why small blood tests can falsely reassure patients
- How most genetic panels miss key mutations and immune factors
- What deep mapping reveals about tumor recurrence
- How CIPI (Chemo-Immuno-Precision Injection) targets tumors directly
- Why precision oncology offers better outcomes with fewer side effects
📊 Precision oncology replaces guesswork with molecular-level accuracy — transforming how cancer is detected, treated, and prevented from coming back.
“False reassurance can be deadly. Precision testing finds what others miss.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493